Electra Therapeutics Inc(ETRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 38.62% | Shs Outstand | 62.8M | Perf Week | 1.23% |
| Market Cap | 0.57B | Forward P/E | - | EPS next Y | - | Insider Trans | 12.36% | Shs Float | 38.5M | Perf Month | -33.55% |
| Enterprise Value | - | PEG | - | EPS next Q | -0.43 | Inst Own | 8.74% | Short Float | 1.82% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 1.6% | Short Ratio | 0.9 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.70M | Perf YTD | -39.67% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -41.61% ($15.50) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 6.47% ($8.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.36% 9.69% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.95 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 27.11 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -7.69% ($9.8) | Beta | - | Target Price | $34 |
| Payout | - | Debt/Eq | - | Earnings | 2026/09/02 | SMA50 | -12.96% ($10.4) | Rel Volume | 0.16 | Prev Close | $8.81 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -12.96% ($10.4) | Avg Volume(3M) | 0.78M | Price | $9.05 |
| IPO | 2026/9/18 | Option/Short | No/Yes | Trades | 1596 | Volume | 126,070 | Change | 2.72% |
🧬 면역세포 표면의 신호조절단백질을 겨냥한 항체 신약을 개발하는 미국 바이오테크 기업입니다. 병을 키우는 면역세포를 선택적으로 줄이는 접근으로 중증 염증질환과 암 영역의 후보물질을 키워 왔고, 최근 나스닥 상장으로 임상 자금을 확보했습니다. 제품 매출은 아직 없는 임상 단계 회사입니다.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded less than usual. That is 16% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SCZ iShares MSCI EAFE Small-Cap ETF <0.01% 
DIHP Dimensional International High Profitability ETF <0.01% 
DFIC Dimensional International Core Equity 2 ETF <0.01% 
DFSI Dimensional International Sustainability Core 1 ETF <0.01% 
DXIV Dimensional International Vector Equity ETF <0.01% It ranks #207 of 595 in the industry
Based on market cap of $568M.
PHAT#206 Phathom Pharmaceuticals Inc $569M PER - ETRA#207 Electra Therapeutics Inc $568M PER - 
PBYI#208 Puma Biotechnology Inc $563M PER 21.1 
ACRS#209 Aclaris Therapeutics Inc $561M PER - 
STTK#210 Shattuck Labs Inc $560M PER - 
FAQ
What kind of company is ETRA?
ETRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ETRA?
The market cap of ETRA is approximately $568M, ranking 3,042 within its sector.
What is the 52-week high and low for ETRA?
ETRA has recorded a 52-week high of $15.50 and a low of $8.50.
